cat no | io1028
ioOligodendrocyte-like cells
Human iPSC-derived oligodendrocyte-like cells
ioOligodendrocyte-like cells are highly characterised cells that resemble a pre-myelinating oligodendrocyte state. These cells enable the screening of compounds that modulate myelination, supporting drug development for neurodegenerative and demyelinating diseases, such as multiple sclerosis.
Place your order
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
Benchtop benefits
Defined
Human O4+ cells initially display a typical OPC-like morphology. They mature into oligodendrocyte-like cells that have multiple branched processes.
Quick
O4+ cells are ready from day 1 post-revival and rapidly mature into O4+ MBP+ oligodendrocyte-like cells with an 8 day protocol.
Easy to use
Cryopreserved cells arrive ready to be used upon revival. Simple monolayer culture protocol. No lentiviral transduction required.
Ready within days
The opti-ox powered cells rapidly mature, transitioning into an oligodendrocyte-like morphology within 8 days
Time-lapse video capturing the rapid and homogeneous acquisition of an OPC-like morphology and maturation towards an oligodendrocyte-like morphology with multiple branched processes, upon thawing of cryopreserved cells. 8 day time course; scale bar: 500 渭m.
Generation of experimental readouts within 8 days post-revival
Schematic overview of the timeline in the user manual
ioOligodendrocyte-like cells are delivered in a cryopreserved format and are programmed to rapidly mature upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Induction which is carried out at 无忧短视频, Stabilisation for 1 day (Phase 1), and Maturation from day 1 to day 8 (Phase 2). Phases 1 and 2 after revival of cells are carried out by the customer.
Highly characterised and defined
ioOligodendrocyte-like cells express oligodendroglial-specific markers
Immunofluorescent staining of the cells at day 1 (upper panel) and day 8 (lower panel) post-revival. At day 1, the cells are positive for the oligodendrocyte-specific marker O4 (red), and the DAPI counterstain (blue). At day 8, ioOligodendrocyte-like cells show an increased complexity and are positive for O4 (red), the myelin basic protein (MBP) (green), and the DAPI counterstain (blue). 100X magnification; scale bar: 100 渭m.
View the step-by-step immunofluorescent staining protocol used to generate this data
Cells show an oligodendrocyte-like morphology by day 8
Upon deterministic programming, cells show rapid morphological changes, acquiring an OPC-like morphology by day 1 post-revival. By day 8, cells have matured and display an oligodendrocyte-like morphology. Brightfield images show day 1 and day 8 post-thawing; scale bar: 400 渭m.
Key oligodendroglial genes are expressed by ioOligodendrocyte-like cells
Following deterministic programming, the cells downregulate expression of the pluripotency gene OCT4, whilst demonstrating robust expression of relevant oligodendroglial markers, including PDGFRA, PLP1, MBP, CNP, MAG, and MYRF. Gene expression levels assessed by RT-qPCR, data expressed relative to the reference (housekeeping) gene, HMBS. Data represents day 1 and day 8 post-revival samples; n=2 technical replicates.
Single cell RNA-sequencing shows ioOligodendrocyte-like cells express typical oligodendroglial markers and display increased maturity by day 8
Single cell RNA-sequencing analysis was performed on ioOligodendrocyte-like cells at two timepoints: day 1 and day 8; iPSCs represent the parental non-induced human iPSC line. By day 1, the cell population exhibits a distinct expression profile characteristic of oligodendroglial cells, demonstrated by the expression of oligodendrocyte progenitor genes such as PDGFRA and PTPRZ1. By day 8, there is an increase in the expression of genes associated with mature oligodendrocytes, such as MBP, PLP1, CNP, MYRF and MAL, indicating that the cell population has matured towards an oligodendrocyte-like identity. Gene expression was assessed by Parse Biosciences single cell RNA-sequencing.
Complex multi-cellular modeling
ioOligodendrocyte-like cells show increased MBP expression when in co-culture with ioGlutamatergic Neurons
The enhancement of MBP expression in a co-culture model provides a valuable in vitro cellular model for scientists studying neurons and oligodendrocytes interactions
(A) Immunofluorescent staining of a co-culture of ioOligodendrocyte-like cells expressing the oligodendrocyte marker MBP (green) and ioGlutamatergic Neurons pan-neuronal marker TUBB3 (red), and DAPI counterstain (blue). Co-cultures were analysed on day 7, day 11 and day 17.
(B) Graph shows that the co-culture of ioOligodendrocyte-like cells (represented as OLCs) with ioGlutamatergic Neurons (represented as Neurons) increases the number of MBP-positive cells over time (day 14 vs day 7) relative to ioOligodendrocyte-like cells mono-culture. High-content imaging and a custom algorithm were used to quantify the number of MBP-positive cells. n=2 technical replicates; One-way ANOVA with Tukey鈥檚 multiple comparison or unpaired T-test; *p<0.05; **p<0.005; ****p<0.0001; not-significant not indicated.
Data courtesy of Bsibsi, M. et al., 2024, .
Quad-culture model with ioOligodendrocyte-like cells, ioGlutamatergic Neurons, ioMicroglia and human iPSC-derived astrocytes
Complex multi-cellular models have the potential to provide insights into the role of glial cells in disease mechanisms of neurodegenerative diseases, such as Alzheimer鈥檚 disease and multiple sclerosis.
Immunofluorescent staining of a multi-cellular culture including ioOligodendrocyte-like cells expressing MBP (green), ioGlutamatergic Neurons expressing NF-200 (red) and TUBB3 (red), ioMicroglia expressing IBA1 (yellow), human iPSC-derived astrocytes expressing S100B (yellow), and DAPI counterstain (blue). Cultures were analysed on day 14.
Data courtesy of Bsibsi, M. et al., 2024, , presented in a poster at the Society of Neuroscience 2024 meeting.
Compound screening in co-cultures
Treatment with Tasin-1 leads to increase in MBP expression
The enhancement in MBP expression in response to compound treatment indicates that the cells can be used for compound screening in early stage drug discovery workflows.
Treatment of ioOligodendrocyte-like cells with Tasin-1, a small molecule inhibitor of cholesterol biosynthesis enzymes and described as a pro-myelinating compound by , resulted in a significant increase in the number of MBP-positive cells. MBP quantification was performed using high-content imaging and a custom-developed algorithm. Timepoint day 14; n=2 technical replicates; One-way ANOVA with Tukey鈥檚 multiple comparison or unpaired T-test; *p<0.05; **p<0.005; ****p<0.0001; not-significant not indicated.
Data courtesy of Bsibsi, M. et al., 2024, .
Lot-to-lot consistency for experimental reproducibility
.png?width=1715&height=396&name=ioOligodendrocyte-PCA_AllSamples2%20(1).png)
Bulk RNA-sequencing analysis was performed on three different lots of manufactured product at day 1 and day 8 post revival. Principal component analysis (PCA) represents the variance in gene expression between the three different lots of ioOligodendrocyte-like cells. This analysis shows lots clustering very closely which demonstrates high consistency at each given timepoint. This lot-to-lot consistency in every vial gives scientists confidence in their experimental reproducibility. Colours represent the parental non-induced hiPSC cell line and the three lots of ioOligodendrocyte-like cells; shapes represent different timepoints.
Expression levels for specific genes of interest can be requested by contacting our team at technical@无忧短视频.
Hoescht(blue)_day12v2.png?width=604&name=无忧短视频_ioGlutamatergic%20Neurons_20xMAP2(red)Hoescht(blue)_day12v2.png)
Could specific glial cell behaviours drive the progression of diseases like multiple sclerosis or Alzheimer鈥檚?
Watch this insightful webinar featuring Dr. Valentina Fossati, Senior Research Investigator at the New York Stem Cell Foundation, and In锚s Ferreira, Senior Product Manager at 无忧短视频.
ioCells catalogue
Human iPSC-derived cells
powered by opti-ox
Consistent. Defined. Scalable.
ioWild Type Cells
ioWild Type Cells
ioWild Type Cells
ioDisease Model Cells
ioDisease Model Cells
ioWild Type Cells
ioWild Type Cells
ioDisease Model Cells
ioDisease Model Cells